Abstract Office Background with Silhouette

The Prescription Drug Price Disclosure Program (formerly called Drug Cost Transparency Program) has been moved from the Health and Human Services to the Texas Department of State Health Services beginning September 1, 2021.

In 2021, the 88th Texas Legislature passed House Bill 1033 relating to prescription drug price disclosure. The bill amended Health and Safety Code, Chapter 441, entitled Drug Cost Transparency. Changes included transfer of the program to the Department of State Health Services, promulgation of rules, changes to the required submission of data, establishment of a fee and procedures for administrative penalties.

Data submissions to this website will continue as normal until January 1, 2022 when the new proposed rules will be effective, at which point the transfer will occur and the new process initiated. There will be no interruption in data submission.

The prescription drug price disclosure information, the annual wholesale acquisition cost information and the price increase reporting, will continue to be updated regularly and will remain available.

Program overview

In 2019, the 86th Texas Legislature passed House Bill 2536, relating to drug cost transparency. HB 2536 added new Chapter 441, Drug Cost Transparency, to the Texas Health and Safety Code. Chapter 441 requires pharmaceutical drug manufacturers to report to the Health and Human Services Commission (HHSC) the current wholesale acquisition cost (WAC) of U.S. Food and Drug Administration-approved drugs sold in or into Texas. Pharmaceutical drug manufacturers also are required to separately report specific information related to WAC increases. Drug cost information will be available to the public on this website.